Immunoliposomes as targeted delivery vehicles for cancer therapeutics (Review)

Area of Science:

• Nanotechnology
• Biomedical Engineering
• Oncology

Background:

• Liposome technology has advanced, leading to stealth and cationic liposomes used in clinical trials for cancer treatment.
• Despite progress, achieving specific tumor targeting with current liposome formulations remains a challenge.
• Antibodies are being attached to liposomes to create immunoliposomes for enhanced tumor cell recognition.

Purpose of the Study:

• To explore the potential of immunoliposomes as targeted delivery vehicles for cancer therapy.
• To investigate the anti-tumor properties of immunoliposomes in vitro and in vivo.
• To highlight the need for optimizing antibody coupling methods in immunoliposome construction.

Main Methods:

• Development of immunoliposomes by attaching antibodies to liposome surfaces.
• Evaluation of immunoliposome binding specificity to tumor cells in animal models.
• Assessment of anti-tumor efficacy of immunoliposomes both in vitro and in vivo.

Main Results:

• Immunoliposomes demonstrated preferential binding to specific tumor cells in preclinical models.
• Immunoliposomes exhibited significant anti-tumor properties.
• The optimal method for antibody conjugation to liposomes requires further determination.

Conclusions:

• Immunoliposomes represent a promising approach for targeted cancer therapy.
• Further optimization of immunoliposome construction, particularly antibody coupling, is crucial for clinical success.
• Targeted delivery vehicles like immunoliposomes hold great potential for improving cancer treatment outcomes.